Zobrazeno 1 - 8
of 8
pro vyhledávání: '"C L Tiggelaar"'
Autor:
P.Z. Vörde sive Vörding, A. Bakhshandeh, H. Bailey, C L Tiggelaar, G. J. Wiedemann, Dirk Jäger, Walter L. Longo, A.M. Westermann, W. Gillis, Dörthe M. Katschinski, A. Neumann, Elke Jäger, Alexander Knuth, S.O. Peters, J. D. P. Van Dijk, H. I. Robins, J. Finet
Publikováno v:
Oncology. 64:312-321
Background: Based on earlier clinical and preclinical studies, we conducted a phase II trial in metastatic sarcoma patients of the combination of 41.8°C (×60 min) radiant heat (Aquatherm®) whole-body hyperthermia (WBH) with ‘ICE’ chemotherapy.
Autor:
C L Tiggelaar, G. J. Wiedemann, Volker Bath, Benjamin M Lerner, Afsaneh Bakhshandeh, Walter L. Longo, H. Ian Robins
Publikováno v:
Journal of Oncology Pharmacy Practice. 5:131-134
Autor:
D Paul, Kutz M, H.I. Robins, Dörthe M. Katschinski, C L Tiggelaar, F. D'oleire, G. J. Wiedemann, E. Grosen, D. Spriggs, W. Gillis
Publikováno v:
Cancer Letters. 97:195-201
The potential for 41.8 degrees C whole body hyperthermia (WBH) to enhance ionizing irradiation and cytotoxic chemotherapy without a commensurate increase in normal tissue toxicity is currently receiving renewed clinical interest. Additionally, WBH ma
Autor:
Alexander Knuth, Elke Jäger, Dörthe M. Katschinski, P. J. Zum Vörde Sive Vörding, C L Tiggelaar, E. Grosen, H. I. Robins, Dirk Jäger, G. J. Wiedemann, Julian C. Schink, A Neuman, R. C. Rietbroek, J. D. P. Van Dijk, A.M. Westermann
Publikováno v:
European journal of cancer (Oxford, England, 37(9), 1111-1117. Elsevier Limited
The aim of this study was to determine whether the addition of whole body hyperthermia (WBH) to carboplatin (CBDCA) can induce responses in patients with platinum-resistant ovarian cancer. 16 pretreated patients with platinum-resistant ovarian cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daf738c1f545af20f395ff26c9227a50
https://pure.amc.nl/en/publications/a-pilot-study-of-whole-body-hyperthermia-and-carboplatin-in-platinumresistant-ovarian-cancer(99303712-280d-4493-b1c7-4bbd305c8382).html
https://pure.amc.nl/en/publications/a-pilot-study-of-whole-body-hyperthermia-and-carboplatin-in-platinumresistant-ovarian-cancer(99303712-280d-4493-b1c7-4bbd305c8382).html
Autor:
H I, Robins, E, Grosen, D M, Katschinski, W, Longo, C L, Tiggelaar, M, Kutz, J, Winawer, F, Graziano
Publikováno v:
The Journal of rheumatology. 26(12)
To test the hypothesis that 41.8 degrees C x 60 min whole body hyperthermia (WBH) induces increased serum levels of soluble necrosis factor receptors (sTNF-R).We tested the serum of cancer patients for changes in sTNF-RI and RII levels, as a function
Autor:
H I, Robins, D M, Katschinski, W, Longo, E, Grosen, G, Wilding, W, Gillis, C, Kraemer, C L, Tiggelaar, D, Rushing, J A, Stewart, D, Spriggs, R, Love, R Z, Arzoomanian, C, Feierabend, D, Alberti, K, Morgan, K, Simon, F, d'Oleire
Publikováno v:
Cancer chemotherapy and pharmacology. 43(5)
To evaluate the feasibilitv of sequencing (based on preclinical modeling) tumor necrosis factor-a (TNF) at two dose levels with melphalan (L-PAM) and 41.8 C whole-body hyperthermia (WBH) for 60 min.Nine patients with refractory cancer were treated fr
Autor:
C. Kraemer, Kendra D. Tutsch, D Paul, D. Alberti, R P Qu, D Rushing, Walter L. Longo, James A. Stewart, C. Feierabend, George Wilding, W. Gillis, David R. Spriggs, H. I. Robins, Kutz M, C L Tiggelaar, F. D'oleire, Rhoda Z. Arzoomanian
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 15(1)
PURPOSE To evaluate the biologic interactions and toxicities of melphalan (L-PAM) combined with 41.8 degrees C whole-body hyperthermia (WBH) for 60 minutes. PATIENTS AND METHODS Sixteen patients with refractory cancer were treated (May 1992 to May 19
Autor:
H I, Robins, M, Kutz, G J, Wiedemann, D M, Katschinski, D, Paul, E, Grosen, C L, Tiggelaar, D, Spriggs, W, Gillis, F, d'Oleire
Publikováno v:
Cancer letters. 97(2)
The potential for 41.8 degrees C whole body hyperthermia (WBH) to enhance ionizing irradiation and cytotoxic chemotherapy without a commensurate increase in normal tissue toxicity is currently receiving renewed clinical interest. Additionally, WBH ma